When GlaxoSmithKline reports its third-quarter earnings on October 23, investors should see if bribery allegations in China, which accounted for over a fourth of its sales last quarter, affected sales in the region. In addition, investors should keep an eye on the competition that GlaxoSmithKline faces in the COPD and skin cancer areas, since it is counting heavily on these treatments to pick up the slack once Advair fades.